Alendronate treatment for infants with osteogenesis imperfecta: Demonstration of efficacy in a mouse model

Pediatric Research

Volumn 52, Issue 5, 2002, Pages 660-670

  McCarthy, Edith A ^a   Raggio, Cathleen L ^a   Hossack, Michael D ^a   Miller, Elizabeth A ^a   Jain, Sargam ^a   Boskey, Adele L ^a   Camacho, Nancy P ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; SODIUM CHLORIDE;

ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE FRAGILITY; BONE GROWTH; BONE MINERAL; CHILD CARE; CONTROLLED STUDY; DRUG EFFICACY; FEMUR; HISTOLOGY; MOUSE; NONHUMAN; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; PRIORITY JOURNAL; SPINE; SPINE DISEASE; TREATMENT OUTCOME;

EID: 0036841770     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/00006450-200211000-00010     Document Type: Article

References (36)

1. Smith R 1995 Osteogenesis imperfecta: The brittle bone syndrome. Curr Orthop 9:28-33
2. Engelbert RHH, Pruijs JEH, Beemer FA, Helders PJM: 1998 Osteogenesis imperfecta in childhood: Treatment strategies. Arch Phys Med Rehabil 79:1590-1593
3. Sillence DO, Senn A, Danks DM 1979 Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101-116
4. Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, Lalic L, Glorieux DF, Fassier F, Bishop NJ 2000 Type V osteogenesis imperfecta: A new form of brittle bone disease. J Bone Miner Res 15:1650-1658
5. Paterson CR, Ogston SA, Henry RM 1996 Life expectancy in osteogenesis imperfecta. BMJ 312:351
6. Castells S 1973 New approaches to treatment of osteogenesis imperfecta. Clin Orthop 93:239-249
7. Antoniazzi F, Mottes M, Fraschini P, Brunelli PC, Tato L 2000 Osteogenesis imperfecta: Practical treatment guidelines. Paediatr Drugs 2:465-488
8. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T 1999 Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonon. J Clin Invest 104:1363-1374
9. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, Suriola S, Chilton KM, Russell RGG 1999 Molecular mechanisms of action of bisphosphonates. Bone 24(5):73S-79S
10. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C 1987 Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16:360-310
11. Huaux JP, Lokeitek W 1988 Is APD a promising drug in the treatment of severe osteogenesis imperfecta? J Pediatr Orthop 8:71-72
12. Lansmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, van de Kamp JJP, Papapoulos SE 1997 Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr 156:792-794
13. Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G 1997 Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 131:622-625
14. Astrom E, Soderhall S 1998 Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 87:64-68
15. Glorieux FH, Bishop N, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:946-947
16. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH 2000 Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85:1846-1850
17. Lepola VT, Hannuniemi R, Kippo K, Lauren L, Jalovaara P, Vaanenen HK 1996 Long-term effects of clodronate on growing rat bone. Bone 18:191-196
18. Ferretti JL, Mondelo N, Capozza RF, Cointry GR, Zanchetta JR, Montuori E 1995 Effects of large doses of olpadronate (dimethyl-pamidronate) on mineral density, cross-sectional architecture, and mechanical properties of rat femurs, Bone 16:285S-293S
19. Chipman SD, Sweet HO, McBride Jr DJ, Davisson MT, Marks Jr SC, Shuldiner AR, Wenstrup RJ, Rowe DW, Shapirt JR 1993 Defective pro alpha 2(1) collagen synthesis in a recessive mutation in mice: A model of human osteogenesis imperfecta. Proc Natl Acad Sci U S A 90:1701-1705
20. Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, Toledano TR, Boskey AL 2001 A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int 69:94-101
21. Cobb JR 1948 Outline for the study of scoliosis. Instructional course lectures. Am Acad Orthop Surg 5:248-260
22. Turner CH, Burr DB 1993 Basic biomechanical measurements of bone: A tutorial. Bone 14:595-608
23. Shimizu C, Coutts RD, Healey RM, Kubo T, Hirasawa Y, Amiel D 1997 Method of histomorphometric assessment of glycosaminoglycans in articular cartilage. J Orthop Res 15:670-674
24. Zar JH, 1999 Biostatistical Analysis. Prentice Hall, New Jersey, pp 260-261
25. Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blank MA 2000 Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 119:866-869
26. Glorieux FH 2001 The use of bisphosphonates in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 14(suppl 6):1491-1495
27. Deak SB, van der Rest M, Prockop DJ 1985 Altered helical structure of a homotrimer of alpha 1 (1) chains synthesized by fibroblasts from a variant of osteogenesis imperfecta. Coll Relat Res 5:305-313
28. Pysklywec MW, Moran EL, Bogoch ER 2000 Changes in cross-sectional geometry of the distal femoral metaphysis associated with inflammatory arthritis are reduced by a bisphosphonate (zoledronate). J Orthop Res 18:734-738
29. Ferretti JL, Delgado CJ, Capozza RF, Cointry G, Montuori E, Roldan E, Perez Lloret A, Zanchetta JR 1993 Protective effects of disodium etidronate and pamidronate against the biomechanical repercussion of betamethasone-induced osteopenia in growing rat femurs. Bone Miner 20:265-276
30. Osterman T, Lauren L, Kuurtamo P, Hannuniemi R, Isaksson P, Kippo K, Peng Z, Vaananen HK, Sellman R 1998 The effect of orally administered clodronate on bone mineral density and bone geometry in ovariectomized rats. J Pharmacol Exp Ther 284:312-316
31. Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ; MK-677/Alendronate Study Group 2001 Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 86:1116-1125
32. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694
33. Cummings SR, Black DM, Vogt TM 1996 Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs. J Bone Miner Res 11(suppl):S102(abstr)
34. Bullough PG 1992 Atlas of Orthopaedic Pathology with Clinical and Radiologic Correlations. Gower Medical Publishing, Philadelphia, pp 5.8-5.12
35. Orcel P, Beaudreuil J 2002 Bisphosphonates in bone diseases other than osteoporosis. Joint Bone Spine 69:19-27
36. Zacharin M, Bateman J 2002 Pamidronate treatment of osteogenesis imperfecta lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 15:163-174